Telix Pharmaceuticals (ASX:TLX) does not expect any material impact on its business or supply chain from the international trade tariffs announced by the US government on April 2, according to a Monday Australian bourse filing.

It noted that it had an extensive US-based manufacturing and distribution infrastructure with third-party manufacturing sites and radiopharmacy partner networks. Pharmaceutical products are currently exempt from the tariffs.

The firm also said that the Food and Drug Administration continues to process applications and information requests, despite reports of changes at the agency, and that the firm has not been notified of any changes to the timelines for its new drug application for Pixclara or biologics license application for Zircaix.

Its shares fell 4% in recent trading on Monday.